Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08046049 in Advanced Melanoma and Other Solid Tumors
NCT05571839Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Jan 2023
- Primary completion
- Jun 2026
- Modality
- Bispecific Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of PF-08046049 + SGN-BB228 in melanoma, non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and 2 more, sponsored by Pfizer. Primary endpoints: Adverse Events at 7 months, Laboratory Abnormalities at 7 months and 1 more. Started Jan 2023; status: terminated.
02
Drugs
PF-08046049 + SGN-BB228
03
Conditions
melanomanon-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic cancer (PC)mesothelioma
Beyond the preview
Go deeper on NCT05571839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05571839.